Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Categories: @cannabis-players   

CV Sciences, Inc. provides specialty pharmaceutical products. The Company focuses on manufacturing, marketing, and selling plant-based CBD products to a range of market sectors, as well as develops CBD-based novel therapeutics utilizing CBD. CV Sciences invests in the scientific evidence necessary to receive self affirmed generally recognized as safe (GRAS) status.
  • Current market environment: negative. Prices of production are 8.6% lower compared to the last 12 months (LTM)
  • Prices of production are at 0.8% percentile over the past 5 years, adjusted for inflation (are close to minimun)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -21.8% (LTM), projected -56.3%
  • Share price is 3.4% higher than minimum and 88.6% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-0.9x vs
    )
  • The company is undervalued by EV / projected EBITDA multiple compared to target level (
    vs
    )

Key Financials (Download financials)

Ticker: CVSI
Share price, USD:  (0.0%)0.03
year average price 0.0465  


year start price 0.0340 2023-12-28

max close price 0.0970 2024-06-05

min close price 0.0300 2024-12-17

current price 0.0300 2024-12-26
Common stocks: 152 599 000

Dividend Yield:  0.0%
FCF Yield LTM / expected: -21.8% / -56.3%
EV / LTM EBITDA: -0.9x
Production prices change from LTM: -8.6%
EV / projected EBITDA:
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 5
Net Debt ($m): -1
EV (Enterprise Value): 4
EBITDA LTM ($m): -4
EV / LTM EBITDA: -0.9x
Price to Book: 2.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / LTM EBITDA and 75% percentile

Potential dynamics

News


2024-11-21prnewswire.com

CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs

2024-08-27prnewswire.com

CV Sciences Launches +PlusHLTH, a New Line of Cannabinoid-Free Supplements

2024-08-13seekingalpha.com

CV Sciences, Inc. (CVSI) Q2 2024 Earnings Call Transcript

2023-11-14Seeking Alpha

CV Sciences, Inc. (CVSI) Q3 2023 Earnings Call Transcript

2023-08-14Seeking Alpha

CV Sciences, Inc. (CVSI) Q2 2023 Earnings Call Transcript

2023-05-15Seeking Alpha

CV Sciences, Inc. (CVSI) Q1 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of Potential,
commodities and currency affecting the company